Business Context and Reporting Period
This Form 8-K was filed by Excaliber Enterprises, Ltd. (now VistaGen Therapeutics, Inc.) on May 23, 2011. The report details corporate governance actions taken by the Board of Directors on the same date, specifically a name change and a stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Name Change: The Company's name was amended from Excaliber Enterprises, Ltd. to VistaGen Therapeutics, Inc.
- Stock Split: A 2-for-1 forward split of outstanding Common Stock was approved.
- Authorized Shares: The number of authorized Common Stock shares was increased from 200,000,000 to 400,000,000.
Outlook and Management Commentary
The name change and stock split are scheduled to become effective on the over-the-counter market upon notification by FINRA regarding the effective date. No specific financial guidance, risk factors, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of the name change and stock split via FINRA announcements.
- Verify the updated ticker symbol and trading status on the over-the-counter market.
- Review subsequent filings for the first financial report under the new corporate name.